AestheFill vs Juvelook
AestheFill and Juvelook both use PDLLA, but they are not one formulation category. AestheFill is commonly documented as PDLLA with CMC in a reconstituted vial, while the Juvelook family combines PDLLA with non-cross-linked HA and includes multiple presentations.
This is a formulation comparison, not a claim that one brand is preferable across indications.
Compact comparison
Section titled “Compact comparison”| Field | AestheFill | Juvelook family |
|---|---|---|
| Core polymer | PDLLA | PDLLA |
| Additional formulation distinction | CMC documented in the common 200 mg vial | Non-cross-linked HA combined with PDLLA |
| Publicly described presentations | Commonly cited 200 mg vial: 154 mg PDLLA + 46 mg CMC | 30 mg, 50 mg, and 200 mg total presentations with different PDLLA + HA amounts |
| Preparation class | Lyophilized product requiring reconstitution | Product-specific dry presentation requiring preparation |
| Company context | REGEN Biotech | VAIM |
The AestheFill composition is reported in a recent consensus paper (consensus 🔗). VAIM’s official Korean product page lists current Juvelook-family quantities: 25.5 mg PDLLA + 4.5 mg HA in 30 mg presentations, 42.5 mg + 7.5 mg in the 50 mg presentation, and 170 mg + 30 mg in 200 mg presentations (Juvelook official page 🔗).
The key distinction is the finished formulation
Section titled “The key distinction is the finished formulation”Calling both products “PDLLA” hides the variables most likely to affect practical interpretation:
- Juvelook presentation and total material amount
- presence of non-cross-linked HA
- particle architecture
- preparation volume and process
- intended tissue level and indication
- whether a paper studied the exact current presentation
The early appearance of a PDLLA + HA product cannot automatically be attributed to the same phase as its later tissue response. Nor should HA content be interpreted as equivalent to a conventional cross-linked HA filler.
Preparation must remain product-specific
Section titled “Preparation must remain product-specific”The AestheFill consensus reports a commonly recommended preparation approach, but consensus technique is not a substitute for the current local IFU. Juvelook studies also use differing preparation and injection protocols. Those published methods describe the study intervention; they do not establish one universal family-wide instruction.
Always record the exact Juvelook presentation rather than citing “Juvelook” alone. A 30 mg skin-oriented presentation and a 200 mg volume presentation should not be treated as the same product merely because the brand family is shared.
Evidence boundaries
Section titled “Evidence boundaries”A within-subject study comparing Juvelook Volume with a PLLA product reported improvement on both sides. One PDLLA-treated patient developed moderate swelling and tenderness attributed to localized excess HA; this is a product-and-protocol observation, not a class-wide PDLLA rate (split-face study 🔗).
The broader PDLLA evidence base remains heterogeneous in product, anatomy, preparation, and outcome measures (PDLLA review 🔗).
Practitioner takeaway
Section titled “Practitioner takeaway”The useful question is not “which PDLLA brand?” but “which exact formulation and presentation matches the documented treatment objective?” Continue to the individual AestheFill and Juvelook pages before using any product-specific instruction.